###### Article summary

Article focus
=============

-   This preliminary prospective study investigated three (psychological, nutritional and combined) tailored interventions for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) over time.

-   Differences between the reported changes over time between groups were also assessed.

Key messages
============

-   Psychological, nutritional and combined approaches for the management of ME/CFS influenced symptomatology over time in some individuals with this disorder.

-   Self-reported functional ability (physical and social) are influenced following tailored interventions lasting 3 months.

-   This study provides preliminary evidence that tailored psychological, nutritional and combined interventions may influence self-reported symptomatology in some people with ME/CFS; however, due to the study\'s methodological limitations, it is important that these findings are investigated further in high-quality randomised controlled studies.

Strengths and limitations of this study
=======================================

-   The findings here are an initial step to fill the gap in the extant literature regarding the utility of tailored and multidisciplinary (psychological, nutritional and combined) treatments for ME/CFS.

-   There is bias in this study as the participants were self-selected in the sense that they chose to attend the clinic and which treatment option they preferred (with advice), that is, the study was not randomised.

-   There were low retention rates in this study which may constitute a bias in that those who remained in the study may have experienced benefits and those who experienced little or no benefits may have dropped out.

Introduction {#s1}
============

Myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) is a condition characterised by a prolonged and debilitating fatigue, although the exact cause of this disorder is still under debate. Owing to the lack of a definitive biological marker, diagnosis is made on the basis of the exclusion of other explanatory conditions. The most widely used case definition by the Centers for Disease Control (CDC)[@R1] states that there must be at least 6 months severe fatigue of a new and definite onset, not the result of an ongoing exertion, not alleviated by rest and resulting in reduced levels of physical activity. The CDC definition also sets out a series of minor complaints that must accompany the fatigue (cognitive impairment, sore throat, tender cervical or axillary lymph nodes, muscle pain, multijoint pain, headaches of a new type, pattern or severity at onset, unrefreshing sleep and postexertion malaise), with individuals needing to have the occurrence of four or more symptoms to be diagnosed with ME/CFS. Estimates of the prevalence of ME/CFS have been made as low as 3 and as high as 2800/100 000.[@R2]

The most widely researched strategies for alleviating the symptoms of ME/CFS are the cognitive behaviour therapy (CBT) and graded exercise therapy (GET). Two reviews of studies on CBT[@R3] [@R4] found that it significantly improved physical functioning in adult outpatients as compared with medical management, counselling, guided support, education and support or relaxation. Regarding GET, a systematic review illustrated that this form of therapy was potentially beneficial for people with ME/CFS, especially when combined with a patient education programme.[@R5] However, drop-out rates were higher in the GET groups than control groups suggesting that individuals with ME/CFS are averse to this type of therapy. Recently, a large-scale, longitudinal study investigating the CBT, GET, adaptive pacing therapy (APT) and specialist medical care (SMC) which had very low drop-out rates, found that CBT and GET (when added to SMC) were moderately effective outpatient treatments for this patient group as opposed to APT or SMC alone.[@R6]

Although CBT and GET studies have shown some promising outcomes, there is no known cure for ME/CFS. Therefore the National Institute for Health and Clinical Excellence (NICE)[@R7] recommends a number of symptom management strategies and interventions aimed at helping individuals to cope with their condition and reduce physical deconditioning brought about by the illness. Pharmacological interventions are, at times, suggested for patients with poor sleep or pain, for instance, low-dose antidepressants, as these have been shown to be effective.[@R8; @R9; @R10; @R11; @R12; @R13; @R14] However, patient expectations must be realistic as the drugs may help elevate mood and psychological outlook, but not reduce fatigue and other symptomatology associated with ME/CFS.[@R15] Numerous drugs such as thyroxin, hydrocortisone and antiviral agents are not advised by NICE due to contradictory findings.[@R16] [@R17]

In terms of function and quality-of-life management, NICE offers general advice concerning sleep management, appropriate rest periods and pacing. Sleep hygiene instruction, together with pharmacological treatment tailored to the individual patient, can be beneficial in combating fatigue.[@R18] Dietary management may also reduce symptomatology for those with concurrent irritable bowel syndrome,[@R19] although this is not currently recommended by NICE. Dietary supplementation has been investigated in relation to ME/CFS. Fatty acids,[@R20] folic acid,[@R21] vitamin C,[@R22] co-enzyme Q10,[@R23] magnesium,[@R24] multivitamins[@R25] and minerals[@R26] have all been shown to reduce symptomatology in ME/CFS patients. However, other studies have shown conflicting findings with regard to nutritional supplementation, therefore it is perhaps wise to treat with supplements on a case-by-case basis.[@R27] [@R28]

Owing to the lack of clear and definitive treatment strategies, individuals often seek out complementary and alternative medicines (CAM). Although NICE does not recommend the use of CAM they do acknowledge that many people with ME/CFS use such therapies and find them beneficial for symptom management. This view is due to the lack of published evidence for the effectiveness of these treatments. Examples of CAM treatments used by individuals with ME/CFS include religious healing, massage therapy, relaxation, meditation, homoeopathy, acupuncture, naturopathy and herbal therapies;[@R29] [@R30] patient satisfaction with such approaches as CAM has been high, over 80% in some instances.[@R29] A recent systematic review of such interventions identified 70 controlled clinical trials (randomised and non-randomised) and found that 86% of these studies illustrated at least one positive effect, with 74% showing a decrease in illness-related symptomatology.[@R31] Meditative or mindfulness approaches warranted further investigation based on these results as did supplement programmes of magnesium, [l]{.smallcaps}-carnitine and *S*-adenosylmethionine. A subsequent review based solely on randomised controlled trials (RCTs) of CAM techniques identified 26 such studies and observed that qigong, massage and tuina (approaches based within the Chinese traditional medicine and based upon relaxation and connection with the body) illustrated positive effects as did supplementation studies utilising nicotinamide adenine dinucleotide and magnesium.[@R32] However, within both reviews it was noted that the methodological quality of reporting was poor and the sample sizes in these studies were small; hence ability to draw strong conclusions on the efficacy of CAM methods is limited. Porter *et al*[@R31] did note that individualised treatment protocols which include a range of tailored strategies are a promising area for further investigation for this complex, multisystem illness.

Objectives {#s1a}
----------

There is still much debate and uncertainty regarding alternative interventions for those with ME/CFS. A recent review of CAM techniques[@R31] highlight the need for further exploration of individually tailored interventions for the alleviation of the condition\'s often debilitating and an intrusive symptomatology. This study therefore aims to provide preliminary evidence for the utility of three types of approaches (psychological, nutritional and combined) to the management of ME/CFS over time (baseline and follow-up) offered at a private healthcare centre in the UK.

Methods {#s2}
=======

Study design and setting {#s2a}
------------------------

This preliminary prospective study aimed to investigate whether psychological, nutritional and combined approaches to the treatment of ME/CFS influenced symptom report measures over a 3-month time period and whether there were significant differences in these changes among groups. The research was conducted at a private secondary healthcare facility. All potential patients of the clinic were first asked to complete a comprehensive symptom profile and medical history, including questions relating to triggering factors, psychology subtypes and structural/biological subtypes (this is distinct from the research data collected). Subsequent to this, every individual received a 15 min screening with one of the practitioners (please note, this was neither of the authors of the current study) who recommended the best course of action for his/her needs; ie, the psychology-related intervention, nutritional advice and support or a combination of the two.

All individuals requesting treatment at the private care setting were offered the opportunity to participate in the study. Those who expressed an interest (N=145) were emailed a spreadsheet that contained the questionnaires and asked to complete it at their convenience. Informed consent was obtained prior to the completion of the questionnaires and the study was approved by the University of East London Ethics Committee. Participants were told that they could withdraw from the study at any time and that withdrawal would not affect their care at the clinic. Participants were allowed to ask questions at any point during the study and no deception was used as the participants were informed of the nature of the research programme before they agreed to participate. Subsequently, participants were requested to complete the questionnaire pack on a second occasion, 3 months from the baseline measures.

### Psychology {#s2a1}

The clinic offers a 3-month intervention which consists of a combination of neuro-linguistic programming (NLP), emotional freedom technique (EFT), life coaching and hypnotherapy/self-hypnosis constructed in a manner specific to the needs of those with ME/CFS. The primary aim of this approach is to reduce the anxiety that is associated with having a debilitating and unpredictable condition, improve emotional well-being and help individuals slowly manage and increase their activity within their own limits (ie, pacing). The programme is offered as a series of group sessions and the peer support is seen as an important component of the intervention, which is solidified via the use of moderated online support forums, narratives of previous clients' experiences and online materials that can be accessed as often as necessary. In addition to, or as an alternative to this course, individuals receive a series of one-to-one sessions and for the most severely affected ME/CFS patients, telephone sessions are arranged and support materials can be accessed in their own homes.

Over the 3-month period of this preliminary study, the participants experienced one of three treatment options. The first option included 13 h of practitioner contact time in a mix of group training in person, group telephone conference calls and one-to-one telephone sessions, the second option was 4 h of one-to-one telephone sessions and the final option was 3 h of in-person sessions. All participants had access to various support materials which included CDs and online resources. The amount of time spent on these was patient-led, but was in the region of a further 6 h. All the practitioners offering this option are qualified in hypnotherapy, NLP, life coaching and EFT and undergo an intensive period of training in the clinic\'s own integrative approach (please see Howard and Arroll[@R33] for more details of this approach) and ongoing supervision (individual and group supervision on a biweekly basis) from the department director, who is the only senior practitioner in the team.

### Nutrition {#s2a2}

Tailored nutritional therapy is achieved via one-to-one consultations with individuals. To begin, a very detailed history is taken based upon the information given in the aforementioned symptom profile. Qualified nutritional therapists (who have been given specialist training regarding ME/CFS from the clinic) then suggest tests consistent with symptomatology, for instance the Adrenal Stress Index Test, comprehensive stool analysis/gastrointestinal function, vitamin and mineral status, etc. Results from these tests are then used to compose an evidence-driven diet and supplement programme. As most cases of ME/CFS are complex involving multiple body systems, this process is often iterative and follow-up consultations are necessary to check progress and make alterations to the protocol. The nutritional therapy programme consists of an initial 1 h evaluation (which includes the tailored advice) and a follow-up approximately every 6 weeks; therefore, during the course of the present study, the participants received a minimum of two 1 h sessions with email support for any queries and detailed nutritional guidance. All the nutritional therapists are qualified to the diploma level and members of (voluntary) regulatory bodies such as the British Association for Applied Nutrition and Nutritional Therapy and the Complementary and Natural Healthcare Council. Similar to the psychology department, the nutrition department is led by one senior practitioner who supervises the team with individual and group supervisory arrangements.

### Combined {#s2a3}

Within the combined programme, a multidisciplinary approach is taken with practitioners discussing the patients in case meetings to ensure that the psychological and nutritional aspects complement each other to achieve the best outcome. It should be noted that the interventions in the combined programme are phased-in as it was found that asking individuals to engage in numerous therapeutic activities at the same time resulted in high drop-out rates.

Primary outcome measures {#s2b}
------------------------

### Medical Outcomes Survey Short-Form 36 (SF-36) {#s2b1}

This 36-item measure is the short form of the original Medical Outcomes Survey[@R34] to measure functional impairment and contains eight subsections: (1) physical activity limitations due to health problems; (2) social activity limitations due to physical or emotional problems; (3) usual role activity limitations due to physical health problems; (4) bodily pain; (5) general mental health; (6) role activity limitations due to emotional problems; (7) vitality (energy and fatigue) and (8) general health perceptions.[@R34] The items are scored so that higher scores indicate a greater functional ability. In terms of the psychometric properties of this measure, reliability estimates for all subscales are good, exceeding the Cronbach\'s α-coefficient value of 0.70.[@R35] In terms of validity, the Short-Form (SF-36) correlates amply, r≥0.40, with the frequency and severity of numerous symptoms and general health conditions.[@R36] [@R37]

### Multidimensional Fatigue Inventory {#s2b2}

This 20-item measure contains five fatigue dimensions: general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity.[@R38] Items such as 'I tire easily' are rated on a five-point scale (1=yes, that is true; 5=no, that is not true) with lower scores reflecting higher levels of fatigue. The Multidimensional Fatigue Inventory (MFI) has good internal consistency with average Cronbach\'s α-coefficient equalling 0.84 across the subscales. Convergent validity based on a sample of radiotherapy patients found correlations between the subscales and a visual analogue fatigue scale to be 0.77 for general fatigue, 0.70 for physical fatigue, 0.61 for reduced activity, 0.56 for reduced motivation (p\<0.001) to 0.23 for mental fatigue (p\<0.01).[@R38]

Secondary outcome measures {#s2c}
--------------------------

### CDC CFS Symptom Inventory {#s2c1}

CDC CFS Symptom Inventory[@R39] was used to measure specific ME/CFS symptoms and confirm diagnosis. This instrument is based upon the CDC case definition[@R1] and includes a fatigue item and the eight distinct symptoms are also included in the CDC guidelines with an additional 10 associated symptoms. The format of this self-report measure is a six-point scale of perceived frequency (0=absent, 5=all the time) and severity (0=none, 5=very severe). The psychometric properties of this instrument are good: the Cronbach\'s α-coefficient=0.88; r=0.74 convergent validity with the Chalder Fatigue Scale;[@R40] r −0.68 and −0.87 convergent validity with the SF-36 'vitality' and 'bodily pain' subscales, respectively.

### Multidimensional Health Locus of Control Scale {#s2c2}

Multidimensional Health Locus of Control Scale (MHLCS)[@R41; @R42; @R43] measures perceived control via three distinct subscales: 'internal', 'chance' and 'powerful others' which has two dimensions, that of 'doctors' and 'other people'. The instrument contains 18 items in total (six items each for the 'internal' and 'chance' scales and three items for both the 'powerful others' scales) and is scored on a 6-point Likert scale from 'strongly agree' to 'strongly disagree'. Internal reliability of the instrument is good with Cronbach\'s α-coefficients ranging from 0.67 for 'powerful others' to 0.77 for 'internal'. The measure correlates positively and significantly with associated scales from Levenson\'s[@R44] locus of control measure upon which the MHLOC was based, which demonstrates a good convergent validity.[@R41]

Statistical methods {#s3}
===================

The data were initially screened for missing data. Four cases contained substantial amounts of missing data; therefore these were excluded from the analysis (one individual from the nutrition group and three from the combined group). Subsequent analyses were conducted on complete date only. The baseline data were subsequently of the quality for parametric tests, except for the variables CDC CFS swollen lymph nodes and glands, memory problems, abdominal pain and depression. However, the follow-up data suffered from high levels of skew and kurtosis which was not substantially alleviated by data transformation. This violated a key criterion for parametric testing, that of normality of distribution, so non-parametric tests were selected. In addition, as the sample sizes in each individual treatment group were small, the more conservative non-parametric tests were the preferred choice as even though tests such as analysis of variance are generally robust against non-normality, this does not hold true with small sample sizes. One-way analysis of variance tests and Kruskal-Wallis tests (the former for those variables that met the criteria for parametric tests, and the latter that did not) were used to investigate baseline variation and analysis of covariance tests were used to account for this variation and test for differences among the three groups. Wilcoxon sign-rank tests were employed to look for differences over time (baseline and 3-month follow-up) and if differences were significant, percentage change was calculated. Please note, as this is an exploratory study with only one time-point and no control group, any significant findings do not infer clinical significance, rather statistical significance, and as such exact p values are presented.

Results {#s4}
=======

Participants {#s4a}
------------

Of the 145 individuals who expressed an interest in the study, 142 time-one questionnaires were returned, equating a 97.9% response rate at baseline (two participants from the psychology group and one from the combined group dropped out at this stage). Therefore, excluding the four cases deleted due to insufficient data, 138 cases were used for the baseline analysis; 42 participants in the psychology group, 44 in the nutrition group and 52 in the combined group. There was no significant association between gender and group (*χ*^2^ (2)=0.179, p=0.915), all groups consisting of approximately one-fifth males ([table 1](#BMJOPEN2012001079TB1){ref-type="table"}). There was no significant difference in age (F(2, 135)=0.001, p=1.000); in fact group means for age were near identical at 42.881, 42.864 and 42.843 for psychology, nutrition and combined groups, respectively. There was also a non-significant result for illness duration (F(2, 135)=0.252, p=0.778). Therefore, in terms of demographics, the groups were comparable. With regard to the outcome measures, there were significant differences between the groups in terms of the MFI subscale 'general fatigue' (F(2, 135)=3.219, p=0.043), MFI 'physical fatigue' (F(2, 135)=3.343, p=0.038) and the CDC CFS symptom 'swollen lymph nodes and glands' (H(2)=7.161, p=0.028). To investigate the source of these differences, post hoc tests were conducted (unrelated t tests for the fatigue variables and Mann-Whitney tests for swollen lymph glands as the former did not meet criteria for parametric tests, all with Bonferroni correction for multiple comparisons). A significant difference was observed between the psychology and combined groups with regard to general fatigue (t(92)=−2.449, p=0.016) and physical fatigue (t(92)=−2.658, p=0.009) and also between the nutrition and psychology groups in terms of the degree of lymph node and gland swelling (U=635.00, p=0.009). Within the fatigue measures, the combined group reported significantly higher levels of both general and physical fatigue than the psychology group, whereas those undertaking nutritional support stated a higher occurrence of swollen lymph nodes and glands.

###### 

Demographics for gender, age and illness duration across the three treatment groups

                                                             95% CI for mean                       
  ------------------ --------------- -------------- -------- ----------------- -------- ---------- -------
  Gender             Psychology      9 (21.4%)^d^                                       0.179^c^   0.915
  Nutrition          8 (18.2%)^d^                                                                  
  Combined           11 (21.2%)^d^                                                                 
  Total              28 (20.3%)^d^                                                                 
  Age                Psychology      42.881         13.986   38.523            47.239   0.000^a^   1.000
  Nutrition          42.864          12.504         39.062   46.665                                
  Combined           42.843          11.125         39.714   45.972                                
  Total              42.861          12.406         40.765   44.957                                
  Illness duration   Psychology      8.874          8.252    6.302             11.445   0.252^a^   0.778
  Nutrition          10.023          7.375          7.781    12.265                                
  Combined           9.625           7.291          7.595    11.655                                
  Total              9.523           7.580          8.247    10.800                                

(a), c F statistic for one-way analysis of variance; (c), b χ^2^ statistic; (d), a number of males.

### Retention analysis {#s4a1}

Seventy-two of the original 138 participants (14 participants in the psychology group, 27 in the nutrition group and 31 in the combined group) completed the battery of measures at the 3-month follow-up, resulting in retention rates of 52.17% in the study overall, 33.33% in the psychology group, 61.36% in the nutrition group and 59.62% in the combined group. To investigate whether the individuals who did not complete the time-two measures were significantly different from those at baseline on demographic and outcome measures, a series of t tests and Mann-Whitney tests were performed. Those that dropped out of the research (although still receiving treatment at the clinic) differed significantly in terms of age (t(136)=−2.227, p=0.028) and illness duration (t(136)=−2.549, p=0.012). Those who remained in the study were of significantly older age (mean age of those that remained in the study=45.056, SD=11.535; mean age of drop-outs=40.400, SD=12.932) and longer illness duration than those who dropped out (mean age of those that remained in the study=10.836, SD=7.383; mean illness duration of drop-outs=7.571, SD=7.472). Individuals who did not remain in the study did not differ significantly in terms of gender (*χ*^2^ (2)=1.222, p=0.269) or any of the outcome measures.

Comparisons within groups across time {#s4b}
-------------------------------------

### Overall sample {#s4b1}

#### Primary outcomes {#s4b1a}

The following percentage change scores represent statistically significant changes, rather than clinically significant shifts, as this was an exploratory study. In the sample as a whole, there were improvements in all areas of the SF-36 ([table 2](#BMJOPEN2012001079TB2){ref-type="table"}), with a 5.80% improvement in physical functioning, a 68.98% improvement in role limitations due to physical difficulties, a 5.17% improvement in bodily pain, a 26.17% improvement in social functioning, a 5.77% improvement in general mental health, a 10.58% improvement in role limitations due to emotional difficulties, a 22.30% improvement in vitality, energy or fatigue and a 36.49% improvement in general health perception. When looking at the fatigue subscales of the MFI, all five subscales showed significant reductions in fatigue; 8.55% in general fatigue, 10.98% in physical fatigue, 8.81% in reduced activity, 12.96% in reduced motivation and 12.79% in mental fatigue.

###### 

Comparisons across time within the primary outcome measures within the overall sample

                                     N    Baseline   3-Month follow-up   Comparisons                                       
  ---------------------------------- ---- ---------- ------------------- ------------- -------- -------- -------- -------- -------------
                                          Lower      Mdn                 Upper         Lower    Mdn      Upper             
  SF-36 physical functioning         72   18.075     41.644              66.667        25.694   47.222   77.583   −3.120   0.002\*\*
  SF-36 role limitations physical    71   0          0                   0             0        25       50       −4.321   0.001\*\*\*
  SF-36 bodily pain                  72   32.5       56.25               79.375        32.500   67.500   90       −2.240   0.025\*
  SF-36 social functioning           72   12.5       25                  50            12.500   50       75       −4.504   0.001\*\*\*
  SF-36 general mental health        72   53         60                  75            57       68       80       −2.665   0.008\*\*
  SF-36 role limitations emotional   72   0          33.317              100           41.667   66.670   100      −3.159   0.002\*\*
  SF-36 vitality energy or fatigue   72   10         15                  35            11.250   30       45       −4.205   0.001\*\*\*
  SF-36 general health perceptions   72   20         30                  40            25       40       50       −3.996   0.001\*\*\*
  MFI general fatigue                72   15         18                  19            12       16       19       −3.692   0.001\*\*\*
  MFI physical fatigue               72   15         18                  20            12       16       19       −4.591   0.001\*\*\*
  MFI reduced activity               72   11         15                  18            9        14       17       −2.421   0.015\*
  MFI reduced motivation             72   8          10                  13.750        7        9        12       −2.986   0.003\*\*
  MFI mental fatigue                 72   11         14                  18            8.250    12.500   15       −3.661   0.001\*\*\*

**\***Significant at 0.05 level.

**\***\*Significant at 0.01 level.

**\***\*\*Significant at 0.001 level.

Mdn, median; MFI, Multidimensional Fatigue Inventory; SF-36, Short-Form 36.

#### Secondary outcomes {#s4b1b}

Within the CFS Symptom Inventory ([table 3](#BMJOPEN2012001079TB3){ref-type="table"}), there were improvements in occurrence of sore throats (34.48%), diarrhoea (42.47%), fatigue after exertion (16.32%), muscle aches or muscle pains (21.01%), pain in joints (34.55%), chills (37.00%), unrefreshing sleep (19.55%), sleeping problems (17.17%), headaches (24.94%), memory problems (17.86%), difficulty concentrating (26.66%), sinus and nasal symptoms (26.38%), shortness of breath (29.28%), sensitivity to light (28.62%) and depression (39.55%). There were no significant differences from time-one to time-two in the MHLCS subscale of 'chance', 'powerful others' and 'other people' ([table 3](#BMJOPEN2012001079TB3){ref-type="table"}); however, the MHLCS did illustrate significant increases in internal locus of control (30.67%) and that of doctors (47.49%).

###### 

Comparisons across time within the secondary outcome measures within the overall sample

                                       N    Baseline   3-Month follow-up   Comparisons                                     
  ------------------------------------ ---- ---------- ------------------- ------------- ------- ------- -------- -------- -------------
                                            Lower      Mdn                 Upper         Lower   Mdn     Upper             
  CDC CFS sore throat                  70   0          1.5                 4             0       1       2        −2.257   0.024\*
  CDC CFS swollen lymph nodes/glands   71   0          2                   6             0       1       4        −1.567   0.115
  CDC CFS diarrhoea                    72   0          1                   4             0       0       2        −2.481   0.013\*
  CDC CFS fatigue after exertion       72   9          15                  20            6.500   12      16       −3.574   0.001\*\*\*
  CDC CFS muscle aches/pains           72   4          9                   12            1.250   6       12       −3.995   0.001\*\*\*
  CDC CFS pain in joints               70   0          4                   9             0       1       6        −2.908   0.004\*\*
  CDC CFS fever                        70   0          0                   1             0       0       0        −1.667   0.095
  CDC CFS chills                       72   0          2                   6             0       0       2.113    −4.206   0.001\*\*\*
  CDC CFS unrefreshing sleep           72   6          12                  16            4       6       16       −2.295   0.022\*
  CDC CFS sleeping problems            72   2          8                   12            2       4       12       −1.983   0.047\*
  CDC CFS headaches                    71   1          6                   9             1       6       11.250   −2.850   0.004\*\*
  CDC CFS memory problems              72   2          6                   12            1       6       11.250   −2.053   0.040\*
  CDC CFS difficulty concentrating     72   2.500      8.500               12            1       6       12       −3.440   0.001\*\*\*
  CDC CFS nausea                       71   0          1                   4             0       2       6        −0.898   0.369
  CDC CFS abdominal pain               71   0          2                   6             0       2       6        −1.932   0.053
  CDC CFS sinus nasal symptoms         71   1          4                   6             0       1       6        −2.862   0.004\*\*
  CDC CFS shortness of breath          69   0          2                   4             0       1       4        −2.402   0.016\*
  CDC CFS sensitivity to light         71   0          2                   6             0       1       4        −2.388   0.017\*
  CDC CFS depression                   72   0          2                   6             0       1       4        −2.297   0.022\*
  MHLCS internal                       72   0.528      0.681               0.799         0.611   0.722   0.889    −2.962   0.003\*\*
  MHLCS chance                         72   0.222      0.344               0.417         0.201   0.320   0.444    −1.552   0.121
  MHLCS powerful others                72   0.333      0.389               0.500         0.306   0.361   0.500    −1.601   0.109
  MHLCS doctors                        72   0.0833     0.139               0.222         0.083   0.111   0.194    −2.381   0.017\*
  MHLCS other people                   72   0.194      0.250               0.3056        0.174   0.250   0.278    −1.186   0.236

**\***Significant at 0.05 level.

**\***\*Significant at 0.01 level.

**\***\*\*Significant at 0.001 level.

CDC CFS, Centers for Disease Control Chronic Fatigue Syndrome Inventory; CFS, chronic fatigue syndrome; Mdn, median; MHLCS, Multidimensional Health Locus of Control Scale.

### Psychology group {#s4b2}

#### Primary outcomes {#s4b2a}

Within the group of individuals who opted for a purely psychological intervention, improvements were seen in physical functioning (16.75%), role limitations due to physical problems (84.61%), social functioning (37.81%), general mental health (19.15%), vitality, energy or fatigue (49.57%) and general health perceptions (19.01%). Also, all the MFI fatigue scales decreased over a 3-month period, 13.58% in general fatigue, 17.74% in physical fatigue, 23.20% in reduced activity, 11.42% in reduced motivation and 29.66% in mental fatigue ([table 4](#BMJOPEN2012001079TB4){ref-type="table"}).

###### 

Comparisons across time within the primary outcome measures within the psychology group

                                     N    Baseline   3-Month follow-up   Comparisons                                       
  ---------------------------------- ---- ---------- ------------------- ------------- -------- -------- -------- -------- -----------
                                          Lower      Mdn                 Upper         Lower    Mdn      Upper             
  SF-36 physical functioning         14   25.008     44.444              58.367        27.083   69.450   84.700   −2.707   0.007\*\*
  SF-36 role limitations physical    14   0          0                   25            0        50       81.250   −2.379   0.017\*
  SF-36 bodily pain                  14   39.375     57.500              80.625        32.500   72.500   90       −1.195   0.232
  SF-36 social functioning           14   25         37.500              50            34.375   56.250   90.625   −2.689   0.007\*\*
  SF-36 general mental health        14   47         62                  80            67       76       88       −2.497   0.013\*
  SF-36 role limitations emotional   14   24.974     100                 100           58.336   100      100      −0.842   0.400
  SF-36 vitality energy or fatigue   14   10         20                  40            28.750   45       52.500   −3.066   0.002\*\*
  SF-36 general health perceptions   14   23.750     30                  41.250        31.250   40       63.750   −2.561   0.010\*
  MFI general fatigue                14   14         16.500              18.500        9.750    13.500   18.500   −2.657   0.008\*\*
  MFI physical fatigue               14   13.750     16                  19.250        8.750    13       16.750   −2.810   0.005\*\*
  MFI reduced activity               14   9.750      12.500              18.250        7        9        14.500   −2.142   0.032\*
  MFI reduced motivation             14   5.750      8                   11.750        4.750    5.500    8.250    −2.131   0.033\*
  MFI mental fatigue                 14   11.750     15.500              18            6.500    9.500    15       −2.950   0.003\*

**\***Significant at 0.05 level.

**\***\*Significant at 0.01 level.

Mdn, median; MFI, Multidimensional Fatigue Inventory; SF-36, Short-Form 36.

#### Secondary outcomes {#s4b2b}

Within those taking part in the psychology intervention, ratings of muscle aches or muscle pains (10.34%), chills (23.40%), memory problems (44.73%), difficulty concentrating (39.50%) and sensitivity to light (64.58%) decreased. A significant increase of 17.56% was observed in internal locus of control, a decrease of 4.67% in the perception that chance played an influential part in the individuals' lives ([table 5](#BMJOPEN2012001079TB5){ref-type="table"}).

###### 

Comparisons across time within the secondary outcome measures within the psychology group

                                       N    Baseline   3-Month follow-up   Comparisons                                    
  ------------------------------------ ---- ---------- ------------------- ------------- ------- ------- ------- -------- -----------
                                            Lower      Mdn                 Upper         Lower   Mdn     Upper            
  CDC CFS sore throat                  14   0          2                   6             0       0       2.500   −1.365   0.172
  CDC CFS swollen lymph nodes/glands   14   0          0.5                 2.5           0       0       4       −0.341   0.733
  CDC CFS diarrhoea                    14   0          0                   2             0       0       2.500   −0.730   0.465
  CDC CFS fatigue after exertion       14   9          12                  20            7.750   9       14      −1.550   0.121
  CDC CFS muscle aches/pains           14   4          9                   15.25         1.750   9       14      −2.145   0.032\*
  CDC CFS pain in joints               14   0          2.5                 9             0       0.500   4.500   −1.778   0.075
  CDC CFS fever                        14   0          0                   1.5           0       0       0.500   −0.135   0.892
  CDC CFS chills                       14   0          1                   6.75          0       0       4.500   −1.970   0.049\*
  CDC CFS unrefreshing sleep           14   9          12                  15.25         5.500   9       16      −0.802   0.422
  CDC CFS sleeping problems            14   2.75       7                   12            1       3       9.750   −1.738   0.082
  CDC CFS headaches                    14   1          2.5                 6             0.750   1       6.750   −1.200   0.230
  CDC CFS memory problems              14   1          6                   9             0.750   1       6.750   −1.965   0.049\*
  CDC CFS difficulty concentrating     14   3.5        9                   17            1       5       6.750   −2.809   0.005\*\*
  CDC CFS nausea                       14   0          0                   4.25          0       1       4.500   −0.213   0.832
  CDC CFS abdominal pain               14   0          2                   5.25          0       0       6       −0.343   0.732
  CDC CFS sinus nasal symptoms         14   1          3.5                 4.5           0       1.500   4.500   −0.724   0.469
  CDC CFS shortness of breath          14   0          1.5                 4.5           0       0.500   2.50    −1.556   0.120
  CDC CFS sensitivity to light         14   0          1                   4.5           0       0       1.250   −1.973   0.049\*
  CDC CFS depression                   14   0          1.5                 6             0       0       2       −1.614   0.106
  MHLCS internal                       14   0.556      0.653               0.840         0.611   0.872   0.923   −2.983   0.003\*\*
  MHLCS chance                         14   0.326      0.417               0.535         0.167   0.361   0.451   −2.594   0.009\*\*
  MHLCS powerful others                14   0.319      0.375               0.451         0.299   0.356   0.431   0.000    1.000
  MHLCS doctors                        14   0.083      0.125               0.194         0.083   0.083   0.174   −1.122   0.262
  MHLCS other people                   14   0.194      0.236               0.285         0.194   0.222   0.257   −0.118   0.906

**\***Significant at 0.05 level.

**\***\*Significant at 0.01 level.

CDC CFS, Centers for Disease Control Chronic Fatigue Syndrome Inventory; CFS, chronic fatigue syndrome; Mdn, median; MHLCS, Multidimensional Health Locus of Control Scale.

### Nutrition group {#s4b3}

#### Primary outcomes {#s4b3a}

The nutrition group saw improvements in role limitations due to physical problems (75.28%), social functioning (24.93%), vitality, energy or fatigue (35.35%) and general health perceptions (29.73%). Once again, all the MFI fatigue scales decreased over a 3-month period, 13.39% in general fatigue, 15.00% in physical fatigue, 13.28% in reduced activity, 14.64% in reduced motivation and 12.83% in mental fatigue ([table 6](#BMJOPEN2012001079TB6){ref-type="table"}).

###### 

Comparisons across time within the primary outcome measures within the nutrition group

                                     N    Baseline   3-Month follow-up   Comparisons                                       
  ---------------------------------- ---- ---------- ------------------- ------------- -------- -------- -------- -------- -----------
                                          Lower      Mdn                 Upper         Lower    Mdn      Upper             
  SF-36 physical functioning         27   16.7       44.444              77.778        16.700   38.889   77.778   −1.136   0.256
  SF-36 role limitations physical    26   0          0                   0             0        25       25       −2.878   0.004\*\*
  SF-36 bodily pain                  27   32.5       45                  67.5          35.200   67.500   90       −1.800   0.072
  SF-36 social functioning           27   0          25                  50            12.500   37.500   75       −2.476   0.013\*
  SF-36 general mental health        27   52         60                  72            52       64       80       −1.696   0.090
  SF-36 role limitations emotional   27   0          0                   100           0        66.670   100      −1.788   0.074
  SF-36 vitality energy or fatigue   27   5          15                  35            15       25       45       −2.734   0.006\*\*
  SF-36 general health perceptions   27   20         25                  35            25       35       45       −2.157   0.031\*
  MFI general fatigue                27   15         18                  19            12       15       19       −2.548   0.011\*
  MFI physical fatigue               27   14         18                  19            11       16       19       −2.791   0.005\*\*
  MFI reduced activity               27   10         14                  18            8        13       16       −2.164   0.030\*
  MFI reduced motivation             27   8          10                  12            6        8        12       −1.985   0.047\*
  MFI mental fatigue                 27   11         13                  16            8        13       15       −2.082   0.037\*

**\***Significant at 0.05 level.

**\***\*Significant at 0.01 level.

Mdn, median; MFI, Multidimensional Fatigue Inventory; SF-36, Short-Form 36.

#### Secondary outcomes {#s4b3b}

In the nutrition group, numerous symptom-related indices also showed improvements ([table 7](#BMJOPEN2012001079TB7){ref-type="table"}); sore throat (56.23%), swollen lymph glands (21.21%), fatigue after exertion (13.90%), muscle aches or muscle pains (20.56%), chills (40.74%), nausea (16.42%) and abdominal pain (20.16%). No significant differences were found from the baseline to follow-up in the perceived control ([table 7](#BMJOPEN2012001079TB7){ref-type="table"}).

###### 

Comparisons across time within the secondary outcome measures within the nutrition group

                                       N    Baseline   3-Month follow-up   Comparisons                                    
  ------------------------------------ ---- ---------- ------------------- ------------- ------- ------- ------- -------- -------------
                                            Lower      Mdn                 Upper         Lower   Mdn     Upper            
  CDC CFS sore throat                  27   8          1                   2             0       1       2       −2.211   0.027\*
  CDC CFS swollen lymph nodes/glands   26   20         0                   5             0       1       12      −2.051   0.040\*
  CDC CFS diarrhoea                    27   16         0                   1             0       0       1       −1.649   0.099
  CDC CFS fatigue after exertion       27   25         9                   16            4       12      20      −2.209   0.027\*
  CDC CFS muscle aches/pains           27   20         4                   9             2       6       12      −2.901   0.004\*\*
  CDC CFS pain in joints               26   20         0.750               4             0       1       6       −1.827   0.068
  CDC CFS fever                        26   9          0                   0             0       0       0       −1.254   0.210
  CDC CFS chills                       27   12         1                   3             0       0       1       −3.401   0.001\*\*\*
  CDC CFS unrefreshing sleep           27   25         6                   12            4       6       16      −1.421   0.155
  CDC CFS sleeping problems            27   25         1                   9             2       4       16      −0.190   0.849
  CDC CFS headaches                    26   25         0.750               6             1       3       6       −1.895   0.058
  CDC CFS memory problems              27   25         2                   6             2       6       12      −0.338   0.735
  CDC CFS difficulty concentrating     27   25         2                   6             4       6       12      −1.196   0.232
  CDC CFS nausea                       26   25         0                   2             0       1       6       −2.407   0.016\*
  CDC CFS abdominal pain               26   16         0.750               3             0       3       6       −2.322   0.020\*
  CDC CFS sinus nasal symptoms         26   20         1                   3.500         0       1       9       −1.244   0.213
  CDC CFS shortness of breath          25   20         0                   2             0       1       3       −1.651   0.099
  CDC CFS sensitivity to light         26   25         0                   4             0       2       6       −1.890   0.059
  CDC CFS depression                   27   20         0                   4             0       2       4       −1.584   0.113
  MHLCS internal                       27   0.944      0.528               0.667         0.528   0.639   0.778   −0.687   0.492
  MHLCS chance                         27   0.694      0.222               0.333         0.222   0.333   0.472   −0.143   0.886
  MHLCS powerful others                27   0.694      0.333               0.389         0.278   0.361   0.528   −1.843   0.065
  MHLCS doctors                        27   0.417      0.0833              0.139         0.083   0.139   0.222   −1.686   0.092
  MHLCS other people                   27   0.833      0.222               0.278         0.167   0.250   0.306   −1.697   0.090

**\***Significant at 0.05 level.

**\***\*Significant at 0.01 level.

**\***\*\*Significant at 0.001 level.

CDC CFS, Centers for Disease Control Chronic Fatigue Syndrome Inventory; CFS, chronic fatigue syndrome; Mdn, median; MHLCS, Multidimensional Health Locus of Control Scale.

### Combined group {#s4b4}

#### Primary outcomes {#s4b4a}

In terms of general health as gauged by the SF-36 measure, the group who received both psychological and nutritional intervention reported reductions in role limitations due to physical difficulties (57.02%), social functioning (22.61%), role limitations due to emotional difficulties (29.47%) and general health perceptions (26.45%). Only one measure of fatigue, that of physical fatigue, saw significant improvements over time (6.42%) in the combined group ([table 8](#BMJOPEN2012001079TB8){ref-type="table"}).

###### 

Comparisons across time within the primary outcome measures within the combined group

                                     N    Baseline   3-Month follow-up   Comparisons                                       
  ---------------------------------- ---- ---------- ------------------- ------------- -------- -------- -------- -------- ---------
                                          Lower      Mdn                 Upper         Lower    Mdn      Upper             
  SF-36 physical functioning         31   22.200     33.333              61.111        27.778   55.556   72.222   −1.850   0.064
  SF-36 role limitations physical    31   0          0                   0             0        25       25       −2.225   0.026\*
  SF-36 bodily pain                  31   32.500     45                  80            32.500   57.500   80       −1.048   0.294
  SF-36 social functioning           31   12.500     25                  37.500        12.500   37.500   62.500   −2.426   0.015\*
  SF-36 general mental health        31   56         60                  72            56       68       76       −0.524   0.600
  SF-36 role limitations emotional   31   0          33.333              100           66.667   66.670   100      −2.313   0.021\*
  SF-36 vitality energy or fatigue   31   10         15                  30            10       25       40       −1.558   0.119
  SF-36 general health perceptions   31   20         30                  40            25       40       55       −2.423   0.015\*
  MFI general fatigue                31   16         18                  19            14       17       19       −0.854   0.393
  MFI physical fatigue               31   15         19                  20            13       17       20       −2.364   0.018\*
  MFI reduced activity               31   12         16                  18            11       16       18       −0.070   0.944
  MFI reduced motivation             31   9          11                  14            8        10       13       −1.082   0.279
  MFI mental fatigue                 31   10         14                  18            11       13       16       −1.586   0.113

**\***Significant at 0.05 level.

Mdn, median; MFI, Multidimensional Fatigue Inventory; SF-36, Short-Form 36.

#### Secondary outcomes {#s4b4b}

Those in the combined group saw significant reductions over the 3-month interval in diarrhoea (47.97%), fatigue after exertion (19.20%), chills (40.23%), headaches (36.18%) and sinus and nasal symptoms (20.56%; [table 9](#BMJOPEN2012001079TB9){ref-type="table"}). No significant differences were found from the baseline to follow-up in the perceived control as measured by the MHLCS in the combined treatment group ([table 9](#BMJOPEN2012001079TB9){ref-type="table"}).

###### 

Comparisons across time within the secondary outcome measures within the combined group

                                       N    Baseline   3-Month follow-up   Comparisons                                    
  ------------------------------------ ---- ---------- ------------------- ------------- ------- ------- ------- -------- -----------
                                            Lower      Mdn                 Upper         Lower   Mdn     Upper            
  CDC CFS sore throat                  29   0          0                   3.500         0       1       2.030   −0.567   0.571
  CDC CFS swollen lymph nodes/glands   31   0          2                   4             0       1       3       −0.725   0.046
  CDC CFS diarrhoea                    31   0          2                   4             0       0       2       −1.996   0.046\*
  CDC CFS fatigue after exertion       31   8          15                  20            6       12      16      −2.392   0.017\*
  CDC CFS muscle aches/pains           31   2          6                   12            1       6       9       −1.908   0.056
  CDC CFS pain in joints               30   0          1.500               8             0       1       4       −1.680   0.093
  CDC CFS fever                        30   0          0                   1             0       0       0.720   −1.383   0.167
  CDC CFS chills                       31   0          2                   6             0       1       2.150   −2.049   0.040\*
  CDC CFS unrefreshing sleep           31   6          12                  16            4       9       16      −1.513   0.130
  CDC CFS sleeping problems            31   1          6                   12            2       4       9       −1.794   0.073
  CDC CFS headaches                    31   2          6                   9             1       3       6       −2.807   0.005\*\*
  CDC CFS memory problems              31   2          6                   12            1       3       9       −1.446   0.148
  CDC CFS difficulty concentrating     31   2          8                   12            1       6       12      −1.899   0.058
  CDC CFS nausea                       31   0          1                   6             0       2       6       −0.855   0.392
  CDC CFS abdominal pain               31   0          1                   6             0       2       4       −0.598   0.550
  CDC CFS sinus nasal symptoms         31   0          5                   8             0       1       4       −2.482   0.013\*
  CDC CFS shortness of breath          30   0          2                   6             0       1       4       −0.976   0.329
  CDC CFS sensitivity to light         31   0          1                   6             0       1       4       −0.787   0.431
  CDC CFS depression                   31   0          2                   6             0       1       6       −1.304   0.192
  MHLCS internal                       31   0.556      0.694               0.861         0.639   0.750   0.889   −1.755   0.079
  MHLCS chance                         31   0.222      0.333               0.361         0.167   0.306   0.417   −0.672   0.501
  MHLCS powerful others                31   0.333      0.389               0.500         0.333   0.389   0.500   −0.577   0.564
  MHLCS doctors                        31   0.111      0.167               0.222         0.083   0.139   0.500   −1.384   0.166
  MHLCS other people                   31   0.167      0.250               0.278         0.194   0.250   0.306   −0.213   0.831

\*Significant at 0.05 level.

\*\*Significant at 0.01 level.

\*\*\*Significant at 0.001 level.

CFS, chronic fatigue syndrome; Mdn, median; MHLCS, Multidimensional Health Locus of Control Scale.

### Comparisons across groups {#s4b5}

With correction for baseline variation, there were no significant differences between the three groups in terms of change scores.

Discussion {#s5}
==========

Key results {#s5a}
-----------

There were statistically significant (rather than known clinically significant) changes over time of numerous measures in all groups investigated. However, this is not to say that these changes were due to the interventions as the design of this study was exploratory, rather than experimental (please see the following sections for a further critique of the design). The psychology group contained the most significant findings, including those concerned with daily functioning, fatigue, locus of control and cognitive CDC CFS-specific symptoms. These findings appear consistent with outcomes from other psychological interventions.[@R3] [@R4] [@R6] As expected, changes in the perceived control were not observed in the nutrition group as this is not an area that is targeted in this programme. However, the more immune-type symptoms such as sore throat and swollen lymph nodes or glands did see significant reductions over time as would be envisaged in treatment protocols based upon nutritional expertise. The group that exhibited the least significant findings was the combined group and, as noted below, this may be due to the greater general severity of symptoms in this group and the need for a more lengthy intervention. Nevertheless, considering the small sample sizes in the groups at the follow-up, these results are very promising and warrant further attention.

Interpretation {#s5b}
--------------

As noted previously[@R31] individualised treatment protocols which include a range of tailored strategies are a favourable direction for dealing with a complex and multisystem disorder such as ME/CFS. The present study has demonstrated that such interventions may be useful in lowering symptomatology, improving functioning and helping individuals gain a greater sense of control over their health status.

Limitations and generalisability {#s5c}
--------------------------------

This study was a preliminary study in a naturalistic setting and as such did not have a robust design. There was not a control group and the participants were not randomly assigned to groups, therefore the results should be treated with caution. To ascertain whether the changes in symptom and functional reports were due to the interventions, an RCT should be conducted. Also, there was a high drop-out rate from time-one to time-two and this rate differed across groups. The highest drop-out rate was in the psychology group; while we cannot be sure why this occurred, it is postulated that the retention was poor in the group as the individuals in the psychology programme had more activities to engage in and may have felt overburdened with the research questionnaires in addition to their sessions and homework (this would not be the case in the combined group as the therapeutic activities are phased-in as mentioned hereinbefore).

In this study, each individual was guided to an appropriate treatment within an initial screening with clinic staff; therefore the group was dependent on the nature of the individual\'s symptoms and their personal choice as the programmes on offer were privately funded. Notably, the groups did differ in general and physical fatigue with participants in the combined groups reporting greater fatigue than those in the psychology group which suggests that this group\'s general symptomatology was more severe. The combined group illustrated less change over time compared to the psychology and nutrition groups and it is feasible to infer that individuals with a greater number and degree of complaints are referred to the combined group within the clinic. Also, those in the combined group will not experience the intensity of each intervention as this has been demonstrated to result in non-compliance; therefore, changes in outcome measures in this group may not be noted at an interval of 3 months. Further studies underway presently will investigate follow-ups at 6 and 12 months to identify whether the findings here are maintained over time and also whether those with a greater symptom severity benefit with a longer intervention. The results from this study will then inform plans for an RCT of the clinic\'s practices. As the participants were self-selected onto these programmes, the findings lack generalisability; future work should sample from the overall ME/CFS population and be randomly assigned to groups to make valid assumptions regarding the illness group as a whole.
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